Hollis D. Showalter

3.9k citations

89 papers · 3.1k indexed · 1 hit paper · h-index 31

Molecular Biology top 5%
Organic Chemistry top 2%
Oncology top 10%
Epidemiology top 10%
Physiology top 0.5%

Co-authors: Paul D. Kirchhoff George A. Garcia Terri L. Boehm Roderick J. Sorenson Alan J. Kraker Nouri Neamati Nicholas J. Donato Tomasz Cierpicki
Topics: Cancer therapeutics and mechanisms (14 papers)Ubiquitin and proteasome pathways (11 papers)Biochemical and Molecular Research (8 papers)
Cited by: Physiology Organic Chemistry Molecular Biology
Journals: Journal of the American Chemical Society Nucleic Acids Research Nature Communications
Partner nations: United States United Kingdom New Zealand

In The Last Decade

Hollis D. Showalter

88 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release

2012 386 citations Hollis D. Showalter et al. profile →

Peers

Countries citing papers authored by Hollis D. Showalter

Since Specialization

Citations

This map shows the geographic impact of Hollis D. Showalter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hollis D. Showalter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hollis D. Showalter more than expected).

Fields of papers citing papers by Hollis D. Showalter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hollis D. Showalter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hollis D. Showalter. The network helps show where Hollis D. Showalter may publish in the future.

Co-authorship network of co-authors of Hollis D. Showalter

This figure shows the co-authorship network connecting the top 25 collaborators of Hollis D. Showalter. A scholar is included among the top collaborators of Hollis D. Showalter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hollis D. Showalter. Hollis D. Showalter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A concise synthesis of 3-substituted-7-amino-6-carboxyl-8-azachromones 2019 ·Tetrahedron Letters ·(unknown),Hollis D. Showalter	2
2	Perturbation of ubiquitin homeostasis promotes macrophage oxidative defenses 2019 ·Scientific Reports ·Marie‐Ève Charbonneau,Karla D. Passalacqua,Susan E. Hagen,Hollis D. Showalter,Christiane E. Wobus,Mary O’Riordan	20
3	Altered Domain Structure of the Prion Protein Caused by Cu2+ Binding and Functionally Relevant Mutations: Analysis by Cross-Linking, MS/MS, and NMR 2019 ·Structure ·Alex J. McDonald,Deborah R. Leon,(unknown),Bei Wu,(unknown),(unknown),Hollis D. Showalter,Philip Andrews,Mark E. McComb,M. Jake Pushie,Catherine E. Costello,Glenn L. Millhauser,David A. Harris	27
4	Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer 2018 ·Pharmacology & Therapeutics ·(unknown),Armand Bankhead,(unknown),Hollis D. Showalter,Nouri Neamati	147
5	Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects 2017 ·Neuropsychopharmacology ·Colleen Carpenter,Alexander G. Zestos,(unknown),Roderick J. Sorenson,Bipasha Guptaroy,Hollis D. Showalter,Robert T. Kennedy,Emily M. Jutkiewicz,Margaret E. Gnegy	23
6	Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C 2016 ·Bioorganic & Medicinal Chemistry ·Colleen Carpenter,Roderick J. Sorenson,(unknown),Szymon Kłossowski,Tomasz Cierpicki,Margaret E. Gnegy,Hollis D. Showalter	12
7	Novel Carboxaldehyde Mediated Synthetic Pathway for 5′-Amino Adenosine Analogues 2015 ·Nucleosides Nucleotides & Nucleic Acids ·Garrett S. Gibbons,Hollis D. Showalter,Zaneta Nikolovska‐Coleska	1
8	Synthesis and structure–activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Paul M. Titchenell,Hollis D. Showalter,Jean‐François Pons,Alistair J. Barber,(unknown),David A. Antonetti	11
9	Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases 2012 ·Journal of Medicinal Chemistry ·(unknown),Hao Xu,Paul D. Kirchhoff,Tomasz Cierpicki,(unknown),Baojie Wan,Nan Zhang,(unknown),Scott G. Franzblau,George A. Garcia,Hollis D. Showalter	24
10	Antiviral Activity of a Small Molecule Deubiquitinase Inhibitor Occurs via Induction of the Unfolded Protein Response 2012 ·PLoS Pathogens ·Jeffrey W. Perry,(unknown),Kyeong‐Ok Chang,Nicholas J. Donato,Hollis D. Showalter,Christiane E. Wobus	70
11	Synthesis and structure–activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Paul D. Kirchhoff,Baojie Wan,Scott G. Franzblau,George A. Garcia,Hollis D. Showalter	12
12	Use of Enterally Delivered Angiotensin II Type Ia Receptor Antagonists to Reduce the Severity of Colitis 2011 ·Digestive Diseases and Sciences ·Manabu Okawada,Hiroyuki Koga,Scott D. Larsen,Hollis D. Showalter,(unknown),Xiaohong Jin,Peter C. Lucas,Elke Lipka,(unknown),Jae Seung Kim,Daniel H. Teitelbaum	21
13	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination 2011 ·Cellular Signalling ·Vaibhav Kapuria,Alexander Levitzki,William G. Bornmann,David S. Maxwell,Waldemar Priebe,Roderick J. Sorenson,Hollis D. Showalter,Moshe Talpaz,Nicholas J. Donato	39
14	A novel synthesis of 3-(substituted)pyrimido[4,5-c]pyridazine-5,7(1H,6H)-diones 2010 ·Tetrahedron Letters ·(unknown),Jeff W. Kampf,Hollis D. Showalter	15
15	Rifamycins – Obstacles and opportunities 2010 ·Tuberculosis ·Paul A. Aristoff,George A. Garcia,Paul D. Kirchhoff,Hollis D. Showalter	140
16	Enediol mimics as inhibitors of the d-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis 2010 ·Bioorganic & Medicinal Chemistry Letters ·Alejandra Yep,Roderick J. Sorenson,Michael R. Wilson,Hollis D. Showalter,Scott D. Larsen,Paul R. Keller,Ronald W. Woodard	14
17	A novel synthesis of N1-(substituted)-pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones 2009 ·Tetrahedron Letters ·(unknown),Hollis D. Showalter	4
18	Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Tuan P. Tran,Edmund L. Ellsworth,Brian M. Watson,Joseph P. Sanchez,Hollis D. Showalter,Michael A. Stier,Martin A. Shapiro,(unknown),Michael D. Huband,(unknown),Samarendra N. Maiti,Tingsheng Li,(unknown),George Thomas,(unknown),Rajeshwar Singh	17
19	A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment 2008 ·Tuberculosis ·Hollis D. Showalter,William A. Denny	54
20	Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases 1997 ·Pharmacology & Therapeutics ·Hollis D. Showalter,Alan J. Kraker	30

About Hollis D. Showalter

Hollis D. Showalter is a scholar working on Organic Chemistry, Molecular Biology and Infectious Diseases, having authored 89 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (14 papers), Ubiquitin and proteasome pathways (11 papers) and Biochemical and Molecular Research (8 papers). The work is most often cited by research in Physiology (337 citations), Organic Chemistry (853 citations) and Molecular Biology (1.8k citations). Hollis D. Showalter has collaborated with scholars based in United States, United Kingdom and New Zealand. Frequent co-authors include Paul D. Kirchhoff, George A. Garcia, Terri L. Boehm, Roderick J. Sorenson, Alan J. Kraker, Nouri Neamati, Nicholas J. Donato, Tomasz Cierpicki, Zepeng Yao and Haoxing Xu. Their work appears in journals such as Journal of the American Chemical Society, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact